Advocacy intelligence hub — real-time data for patient organizations
French Innovative Leukemia Organisation — PHASE2
Chongqing Precision Biotech Co., Ltd — PHASE1, PHASE2
Immune Oncology Research Institute
M.D. Anderson Cancer Center — PHASE2
ELZONRIS: FDA approved
ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
AbbVie — PHASE1, PHASE2
Dana-Farber Cancer Institute — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
ELZONRIS
Stemline Therapeutics, Inc.
ELZONRIS
(Tagraxofusp-erzs)Orphan drugStemline Therapeutics, Inc.
CD123 Interaction [EPC]
12.1 Mechanism of Action Tagraxofusp-erzs is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria to...
Browse all Blastic plasmacytoid dendritic cell neoplasm news →
Naveen Pemmaraju, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Naval Daver, MD, MBBS
M.D. Anderson Cancer Center
📍 HOUSTON, TX
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Arthur E. Frankel, MD, m.d
University of Texas Southwestern Medical Center
📍 ABINGTON, PA
Marie Bleakley, MD
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA
Maryam Fouladi, MD
COG Phase I Consortium
📍 COLUMBUS, OH
View all Blastic plasmacytoid dendritic cell neoplasm specialists →